Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALYPSO trial of eneboparatide in chronic hypoparathyroidism
NL-OMON61002Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of eneboparatide in chronic hypoparathyroidism, sponsored by Alexion Pharmaceuticals. Started Jan 2024; status: active, not recruiting.
02
Drugs
eneboparatide
03
Conditions
chronic hypoparathyroidism
Beyond the preview
Go deeper on NL-OMON61002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61002.